Get the Stockscreener App
29.22
4.59%
-1.42
Avidity Biosciences Inc stock is traded at $29.22, with a volume of 665.38K.
It is down -4.59% in the last 24 hours and down -8.53% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$30.64
Open:
$29.9
24h Volume:
665.38K
Relative Volume:
0.53
Market Cap:
$3.60B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.11
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-4.24%
1M Performance:
-8.53%
6M Performance:
-28.68%
1Y Performance:
+45.38%
1-Day Range:
$29.20
$30.27
1-Week Range:
$28.35
$31.18
52-Week Range:
$16.30
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
29.25 | 3.60B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.02 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.15 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.08 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance UK
Barclays Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00 - MarketBeat
Handelsbanken Fonder AB Invests $788,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Advances RNA Therapeutics for Rare Diseases - TipRanks
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Positive Outlook for Avidity Biosciences Driven by Promising Pipeline Developments and Strong Financial Position - TipRanks
Avidity Biosciences: Promising Drug Pipeline and Potential Approval for DMD44 Drive Buy Rating - TipRanks
How Is Avidity Biosciences Fighting for Rare Disease Patients Beyond Drug Development? - StockTitan
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com UK
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk - Marketscreener.com
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Avidity Biosciences: Promising Clinical Developments and Strong Financial Position Justify Buy Rating - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Avidity Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avidity Biosciences, Inc. SEC 10-K Report - TradingView
Avidity Biosciences reports Q4 EPS (80c), consensus (78c) - TipRanks
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences - BioSpace
Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data (NASDAQ:RNA) - Seeking Alpha
Insiders At Avidity Biosciences Sold US$1.0m In Stock, Alluding To Potential Weakness - Simply Wall St
Avidity Biosciences (RNA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Avidity Biosciences Announces Inducement Grants -February 21, 2025 at 05:50 pm EST - Marketscreener.com
Avidity Biosciences Announces Inducement Grants - TradingView
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Buy" by Analysts - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
(RNA) Proactive Strategies - Stock Traders Daily
Legato Capital Management LLC Invests $301,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 7%Here's Why - MarketBeat
abrdn plc Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 5,875 Shares - MarketBeat
(RNA) Investment Report - Stock Traders Daily
RNA Drug Development Pioneer Joins Codexis: Oligonucleotide Expert Who Created First Approved Antisense Drugs - StockTitan
Avidity Biosciences chief program officer sells $188,918 in stock - MSN
Avidity Biosciences chief program officer sells $188,918 in stock By Investing.com - Investing.com UK
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely - Yahoo Finance
How to Take Advantage of moves in (RNA) - Stock Traders Daily
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6%Here's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Avidity Biosciences CEO Sarah Boyce sells $297k in stock - MSN
Avidity Biosciences' chief medical officer sells shares totaling $112,856 - MSN
Assenagon Asset Management S.A. Invests $1.18 Million in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock - MSN
Avidity Biosciences chief scientific officer sells shares worth $162,191 - MSN
Avidity Biosciences director sells $53,536 in stock - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 3,287 Shares - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 2,959 Shares of Stock - MarketBeat
Sarah Boyce Sells 10,397 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock By Investing.com - Investing.com Canada
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
Feb 03 '25 |
Sale |
32.16 |
5,875 |
188,918 |
50,554 |
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):